Neurocrine Biosciences NBIX Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on trailing twelve months.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's return on assets?
- Neurocrine Biosciences (NBIX) reported return on assets of 15.6% in Q1 2026.
- How has Neurocrine Biosciences's return on assets changed year-over-year?
- Neurocrine Biosciences's return on assets increased by 82.2% year-over-year, from 8.5% to 15.6%.
- What is the long-term trend for Neurocrine Biosciences's return on assets?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's return on assets has grown at a -14.6% compound annual growth rate (CAGR), from 76.4% to 40.7%.
- What does return on assets mean?
- How much profit the company squeezes out of everything it owns.
- How do you interpret return on assets?
- Higher means more productive assets. Unlike ROE, it is unaffected by leverage, so a wide ROE-minus-ROA gap flags a heavily levered balance sheet.
- How does return on assets compare across companies?
- Best compared within an industry — asset intensity varies enormously across sectors. Not meaningful for banks, whose assets are largely financial.